LatestNew Drug Shows Promise in Maintaining Weight Loss and Muscle Mass After GLP-1 Use
Cannabis

Breaking Point in Phoenix: Inside Grow Sciences' Desert Cultivation Excellence

Lindsay MaHarry
Breaking Point in Phoenix: Inside Grow Sciences' Desert Cultivation Excellence
AnxietyChronic Pain
Summary

Grow Sciences in Phoenix showcases Breaking Point, a hybrid cannabis strain gaining recognition for its distinctive aromatic profile and potential therapeutic applications. This strain represents advances in controlled indoor cultivation techniques optimized for desert climates. Breaking Point exhibits characteristics that may benefit patients seeking relief from anxiety and chronic pain conditions. The cultivation facility demonstrates professional growing standards and quality control measures that ensure consistent cannabinoid profiles for medical users in Arizona.

Originally published on

Leafly

By Lindsay MaHarry

Read full article(opens in new tab)

Fetched: August 12, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
Ohio Adult-Use Cannabis Sales Exceed $1.5 Billion Since Market Launch
Cannabis

Ohio Adult-Use Cannabis Sales Exceed $1.5 Billion Since Market Launch

Adult-use cannabis sales in Ohio have surpassed $1.5 billion since legalization in 2024, generating over $55 million in excise tax revenue for host communities. The state Department of Commerce reports a statewide average price of approximately $6.54 per gram. This significant market growth reflects Ohio's successful regulatory framework and expanding consumer access to regulated cannabis products. The tax revenue demonstrates how legalization can fund community programs while establishing a transparent, quality-controlled market that benefits patients seeking therapeutic cannabis options.

23 hours ago
Ganjapreneur
Canadian Government Launches Cannabis and Brain Health Consortium
Cannabis
EpilepsyInsomnia

Canadian Government Launches Cannabis and Brain Health Consortium

Canada is investing $24 million to establish the Canadian Cannabis and Brain Health Consortium, featuring 10 multidisciplinary research teams investigating cannabis's therapeutic potential and effects on brain health. The consortium will examine cannabis use during prenatal exposure, sleep disorders, and its effects on individuals with psychosis, post-traumatic stress disorder, and epilepsy. This comprehensive research initiative aims to generate evidence-based data on cannabis's safety and efficacy for various neurological and psychiatric conditions. The consortium represents a significant effort to understand how cannabis compounds may benefit brain health while identifying potential risks, supporting informed clinical decision-making across Canada.

23 hours ago
Ganjapreneur
Cannabis

Hemp Company Challenges DEA Over HHC Legality Under Farm Bill

A hemp company is challenging the DEA's position on hexahydrocannabinol (HHC), reigniting the legal debate over which cannabinoids are protected under the 2018 Farm Bill. HHC is a semi-synthetic cannabinoid derived from hemp-derived Delta-8 THC, and the litigation centers on whether it falls within the Farm Bill's legal definition of hemp derivatives. This case has significant implications for the cannabis industry and consumers seeking alternative cannabinoid products. The outcome could determine the regulatory status of numerous emerging cannabinoids and shape future enforcement priorities.

yesterday
Cannabis Magazine
Cannabis

Australian Patients Report Barriers to Medical Cannabis Access and Treatment

A qualitative research study examining interviews with Australian patients using medical cannabis oil reveals significant barriers to access and treatment continuity. The research highlights patient experiences with therapeutic cannabis but emphasizes that anecdotal patient reports cannot replace rigorous clinical trials in establishing safety and efficacy. Findings underscore the gap between patient-reported benefits and the need for evidence-based clinical data to guide medical cannabis policy and prescription protocols. This study provides valuable insights into real-world patient challenges while reinforcing the importance of continued clinical research to validate medical cannabis applications across various health conditions.

yesterday
Cannabis Magazine